Form 4 for PLRX PLIANT THERAPEUTICS, INC.
Accepted 2023-08-07 00:00:00 ET · period of report 2023-08-03 · accession 0001209191-23-044892 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-08-07 | 2023-08-03+ | PLRX | Hull Hans | Chief Business Off | S - Sale+OE | $20.01 | -31.3K | 206.1K | -13% | -$626.6K |
| DM | 2023-08-07 | 2023-08-03+ | PLRX | Hull Hans | Chief Business Off | M - OptEx | $2.08 | +10.6K | 207.9K | +5% | +$22.0K |
| DM | 2023-08-07 | 2023-08-03+ | PLRX | Hull Hans | Chief Business Off | M - OptEx | $0.00 | -10.6K | 40.2K | -21% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-04 | S | D | 20,050 | $20.01 | 194,855 | D | — | — | (F3) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.08, inclusive. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. |
| 2 | Common | Common Stock | 2023-08-04 | M | A | 8,791 | $2.08 | 214,905 | D | — | — | |
| 3 | Common | Common Stock | 2023-08-03 | M | A | 1,800 | $2.08 | 207,914 | D | — | — | |
| 4 | Common | Common Stock | 2023-08-03 | S | D | 13,069 | $20.00 | 206,114 | D | — | — | (F2) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.01, inclusive. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. |
| 5 | Common | Common Stock | 2023-08-03 | S | A | 1,800 | $20.00 | 206,114 | D | — | — | (F3) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.08, inclusive. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. |
| 6 | Derivative | Common Stock (Right to Buy) | 2023-08-04 | M | D | 8,791 | $0.00 | 31,367 | D | $2.08 · — to 2028-03-31 | 8,791 Common Stock | (F7) On January 24, 2019, the Reporting Person was granted stock options, the vesting of which was subject to the achievement of pre-established performance criteria which were achieved, and all of which were subject to the Reporting Person's continuous service to the Issuer. |
| 7 | Derivative | Common Stock (Right to Buy) | 2023-08-03 | M | D | 1,800 | $0.00 | 40,158 | D | $2.08 · — to 2028-03-31 | 1,800 Common Stock | (F7) On January 24, 2019, the Reporting Person was granted stock options, the vesting of which was subject to the achievement of pre-established performance criteria which were achieved, and all of which were subject to the Reporting Person's continuous service to the Issuer. |